Get the Deck
Plurify is building PluRNA, a programmable RNA platform for long-term, stable and controllable cell engineering without the complications of genetic editing.
Plurify was spun out of a collaboration between Deep Science Ventures and the Cell and Gene Therapy Catapult to solve real world manufacturing and therapeutic bottlenecks. From day one, our non-negotiables were scalability, safety, cost and speed.
Plurify emerged from DSV's venture-creation process designed to identify high-friction problems in advanced therapy manufacturing and build solutions industry would actually adopt. More than 10 PhD industry insiders and leaders signed off on the technology as a viable solution platform.
The founding team was assembled from industrial biopharma scientists and inventors. The realities of therapeutic R&D guide our product development: manufacturability, scalability, safety and cost come first. Our technology and processes are designed for CMC constraints at bioreactor scale.
PluRNA is now being deployed in industrial settings. Public examples include multiple collaboration with the Cell and Gene Therapy Catapult and early platform adoption from Novo Nordisk, with more going on behind the scenes.
Cell engineering underpins modern biotech, but the current tools force tradeoffs between durability, safety and scalability. PluRNA eliminates those tradeoffs.
There is currently no all-round solution to scalable cell engineering available on the market.
Rather than rewriting the genome, PluRNA acts as a drop-in instruction layer for cells, enabling dynamic programming with long-term output.
Persistent expression without genomic integration, for as long as you want. 100 days? No problem.
Replicating RNA propagates expression, with no epigenetic silencing. Delivery agnostic, as no batch transfection is needed.
Supports inducible multi-gene circuit design. 10KB+ carrying capacity with robust expression.
Leave-no-trace profile. The patients never see it. No risk of integration. Happy regulators.
Our PluRNA platform is disrupting several high-value markets, from streamlining cell therapy engineering and biologics manufacturing to discovery systems and next-generation therapeutics.
Improve differentiation, purity, safety, speed and COGS while maintaining a leave-no-trace profile. Overall streamlining of your GMP CMC process with fewer regulatory concerns.
Replace legacy plasmid-heavy approaches with stable RNA-based producer systems designed for consistency, scale and lower cost.
Build highly customized, portable cell models with inducible pathway programming.
Unlock longer-lasting, multi-gene RNA payloads for programmable in vivo therapies and vaccines.
Our founding team brought together leading-edge industrially-sharpened skills across synthetic biology, bioinformatics and stem cell engineering, each with previous IP in cell and gene therapy development. Supported by a growing and talented team of operators and an advisor network built from leaders in advanced therapies, biotools and manufacturing.
Plurify is a Cambridge, UK based startup built to translate cutting edge biology into real solutions. The operating mix reflects that: scientific depth, innovative instincts, industrial perspective and company-building support.
Co-founder and CEO
Former Novo Nordisk bioinformatics specialist and cell therapy operator, leading strategy, translation, partnerships.
LinkedIn
Co-founder and CTO
Synthetic biology and programmable RNA lead with startup and pharma experience across cloning, transcriptional control and AAV.
LinkedIn
Scientific co-founder
Stem cell engineering expert with deep roots in Cambridge's best labs and the origins of bit.bio. Now Professor at Charite in Berlin.
LinkedIn
Scientist II
Cambridge-trained stem cell scientist helping drive complex RNA biology and cell engineering in the lab.
LinkedIn
Scientist II
Former Astra Zeneca scientist contributing across platform development and expansion, particularly into AAVs.
LinkedIn
COO (fractional)
Operational leadership helping Plurify scale, plan, company-build and execute, with compliance and best practice.
LinkedInExperienced operators from cell and gene therapy, venture creation, manufacturing and RNA therapeutics.
Commercial Advisor
Former CEO of the Cell and Gene Therapy Catapult and a long-standing leader in UK advanced therapies.
LinkedIn
Scientific Advisor
Former CTO at SmartCella bringing deep cell therapy CMC, MSAT, quality and regulatory perspective.
LinkedIn
Scientific Advisor
Former CTO at Clock.bio with prior experience across Mogrify and bit.bio, adding molecular biotech and platform perspective.
LinkedIn
Commercial Advisor
FormerVP at Thermo Fisher. Leader in commercialization, BD and fundraising for cell and gene therapy biotools.
LinkedIn to confirmContributors who helped shape the platform and team during earlier stages of company build-out.
Alumni
Bioinformatics support across sequencing analysis, transcriptional profiling and platform data interpretation.
LinkedIn to confirm
Alumni
Molecular biology consultant supporting experimental development and scientific execution in Cambridge.
LinkedIn
Ex-Board Member
Director Pharma at Deep Science Ventures with extensive biotech creation and company-building experience.
LinkedIn
Ex-Board Member
Chief Business Officer at the Cell and Gene Therapy Catapult with deep business development and deal experience.
LinkedIn
Ex-Board Member
Cell and gene therapy executive with experience from Mogrify, GSK and the Cell and Gene Therapy Catapult.
LinkedInPlurify has been made possible by early investor conviction, strategic partner demand and support from institutions across cell and gene therapy venture creation. Now it's your turn to help us unlock the curative therapies of tomorrow.
We've proven the technology works and protected it with strong IP. We have overwhelming commercial pull with signed MTAs and CDAs, early revenue and active engagement from large biopharma partners. Now we need significant resources to scale into a global platform business.
"The expression levels look extremely bright in neurons compared to other systems I have seen, quite impressive."
Senior Principal Scientist, Novo NordiskCurative cell and gene therapies, biologics and advanced manufacturing all need better cell engineering infrastructure, right as RNA has becoming an accessible modality.
Demand has arrived ahead of team capacity, with partnership conversations already spanning all of our verticals. The industry needs these solutions.
Our platform is protected by a growing patent portfolio covering core technology and applications. We are licensing friendly towards partners and seek maximal impact.
External coverage, announcements, grants and scientific developments tracking how and why Plurify is working with partners, funders and the wider advanced therapy ecosystem.
A high-profile publication reinforcing the team's depth in synthetic transcriptional control and precision gene delivery. Mantas developed this clinical stage AAV to cure glioblastoma.
Mantas explains the industrial purification thesis, PluRNA mechanism and the logic behind solving the problem inside the bioreactor.
A child with spinal muscular atrophy type 1 experienced substantial hepatitis after receiving onasemnogene abeparvovec. They discovered significant remnants of DNA based AAV manufacturing integrated into his liver.
"We see two inevitabilities: the continued growth in cell therapy adoption and the increasing automation of manufacturing processes, together setting the stage for major advances in scalability, cost-efficiency, and reproducibility."
Public grant backing helps validate the importance of Plurify's work in scalable cell engineering and manufacturing.
The collaboration targets safer, more efficacious and less costly cell therapy manufacturing through scalable impurity removal.
Coverage focused on the industrial bottleneck Plurify was created to solve: removing unwanted cells without breaking scale.
Another independent signal that Plurify's approach is resonating with the wider advanced therapy ecosystem.
If you are an aligned investor, scientist, strategic partner or advanced therapy operator, please reach out to contact@plurify.bio